Sign In
Buy AGIO
$27.68
+1.17 (+4.41%)
At Close: Jun 03, 2026
Investment Analysts’ Weekly Ratings Changes for Agios Pharmaceuticals (AGIO)
11:32pm, Sunday, 09'th Aug 2020
A number of research firms have changed their ratings and price targets for Agios Pharmaceuticals (NASDAQ: AGIO): 8/1/2020 – Agios Pharmaceuticals was downgraded by analysts at BidaskClub from a “
Agios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020
11:00am, Thursday, 06'th Aug 2020
CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced t
4,785 Shares in Agios Pharmaceuticals Inc (NASDAQ:AGIO) Bought by Creative Planning
06:56am, Wednesday, 05'th Aug 2020
Creative Planning acquired a new position in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission.
Agios Pharmaceuticals (NASDAQ:AGIO) Given “Buy” Rating at Canaccord Genuity
02:58am, Tuesday, 04'th Aug 2020
Canaccord Genuity reiterated their buy rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a research report released on Friday, AnalystRatings.com reports. They currently have a $72.00 target
Agios Pharmaceuticals Inc (AGIO) Q2 2020 Earnings Call Transcript
02:01am, Friday, 31'st Jul 2020
With me on the call today with prepared remarks are Dr. Jackie Fouse, our Chief Executive Officer; Dr. Chris Bowden, our Chief Medical Officer; Darrin Miles, our Senior Vice President of US Commercial
Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2020 Results - Earnings Call Transcript
03:00pm, Thursday, 30'th Jul 2020
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2020 Results Earnings Conference Call July 30, 2020, 08:00 AM ET Company Participants Holly Manning - Director of Investor Relations Jacqualyn Fouse - Chie
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates
01:55pm, Thursday, 30'th Jul 2020
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 7.75% and 5.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Agios Reports Business Highlights and Second Quarter 2020 Financial Results
11:00am, Thursday, 30'th Jul 2020
– Second Quarter TIBSOVO® Net Revenue of $27.6 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105–115 Million – – Significant Clinical Progress for First-in-Cl
Agios Pharmaceuticals, Inc. 2020 Q2 - Results - Earnings Call Presentation
10:34am, Thursday, 30'th Jul 2020
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2020 Q2 earnings call..
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 29)
Abbott Laboratories (NYSE: ABT)
ABIOMED, Inc. (NASDAQ: ABMD)
Adamis Pharmaceuticals Corp (NASDAQ: ADMP)
Annexon...
Charting a (bullish) holding pattern, S&P 500 digests break to 5-month highs
04:44pm, Tuesday, 28'th Jul 2020
The major U.S. benchmarks are acting well technically, though amid increasingly sideways late-July price action, writes Michael Ashbaugh.
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
12:00am, Sunday, 26'th Jul 2020
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Although there were promising updates from...
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Should You Buy?
04:32pm, Thursday, 23'rd Jul 2020
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charting a bull-flag breakout, S&P 500 extends rally as volatility recedes
04:24pm, Tuesday, 21'st Jul 2020
Technically speaking, the U.S. benchmarks’ bigger-picture backdrop remains bullish, and continues to strengthen, amid recently receding volatility, writes...
Did Hedge Funds Make The Right Call On Agios Pharmaceuticals Inc (AGIO) ?
04:46pm, Friday, 17'th Jul 2020
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest
